Immunogenicity of sequences around HIV-1 protease cleavage sites: Potential targets and population coverage analysis for a HIV vaccine targeting protease cleavage sites-Reference-Cited by-同舟云学术

Immunogenicity of sequences around HIV-1 protease cleavage sites: Potential targets and population coverage analysis for a HIV vaccine targeting protease cleavage sites

Published:2013-06 Issue:29 Volume:31 Page:3000-3008
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Luo Ma,Capina Rupert,Daniuk Christina,Tuff Jeff,Peters Harold,Kimani Makubo,Wachihi Charles,Kimani Joshua,Ball Terry Blake,Plummer Francis A.

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference50 articles.

1. UNAIDS,2013

2. AIDSVAX fails to prove efficacious in large-scale trial;Expert Rev Vaccines,2003

3. HIV vaccine failure prompts Merck to halt trial;Nature,2007

4. Therapeutic vaccine trial shows no benefit;IAVI Rep,2007

5. Characterization of ribosomal frameshifting in HIV-1 gag-pol expression;Jacks;Nature,1988

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A long-term stable cold-chain-friendly HIV mRNA vaccine encoding multi-epitope viral protease cleavage site immunogens inducing immunogen-specific protective T cell immunity;Emerging Microbes & Infections;2024-07-18

2. Immunogenicity of different nanoparticle adjuvants containing recombinant RBD coronavirus antigen in animal model;Biotechnology and Applied Biochemistry;2023-11-30

3. Natural Immunity against HIV-1: Progression of Understanding after Association Studies;Viruses;2022-06-08

4. Nanotechnologies for the delivery of biologicals: Historical perspective and current landscape;Advanced Drug Delivery Reviews;2021-09

5. Assessment of the population coverage of an HIV-1 vaccine targeting sequences surrounding the viral protease cleavage sites in Gag, Pol, or all 12 protease cleavage sites;Vaccine;2021-05